LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

Search

Quidel Corp

Geschlossen

11.05 -0.72

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

10.76

Max

11.3

Schlüsselkennzahlen

By Trading Economics

Einkommen

39M

-92M

Verkäufe

-104M

620M

Gewinnspanne

-14.811

Angestellte

6,500

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+8.18% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

4. Aug. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-140M

560M

Vorheriger Eröffnungskurs

11.77

Vorheriger Schlusskurs

11.05

Quidel Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

13. Mai 2026, 22:54 UTC

Ergebnisse

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13. Mai 2026, 23:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13. Mai 2026, 23:51 UTC

Market Talk

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13. Mai 2026, 23:45 UTC

Market Talk

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13. Mai 2026, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

13. Mai 2026, 23:17 UTC

Ergebnisse

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13. Mai 2026, 23:16 UTC

Ergebnisse

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13. Mai 2026, 23:15 UTC

Ergebnisse

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13. Mai 2026, 23:14 UTC

Ergebnisse

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13. Mai 2026, 23:02 UTC

Market Talk
Ergebnisse

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13. Mai 2026, 22:59 UTC

Market Talk
Ergebnisse

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13. Mai 2026, 22:24 UTC

Ergebnisse

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13. Mai 2026, 22:23 UTC

Ergebnisse

Xero FY International Organic Revenue Growth 25%>XRO.AU

13. Mai 2026, 22:23 UTC

Ergebnisse

Xero FY International Revenue Growth 47%>XRO.AU

13. Mai 2026, 22:22 UTC

Ergebnisse

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13. Mai 2026, 22:19 UTC

Ergebnisse

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13. Mai 2026, 22:19 UTC

Ergebnisse

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13. Mai 2026, 22:18 UTC

Ergebnisse

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13. Mai 2026, 22:16 UTC

Ergebnisse

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13. Mai 2026, 22:15 UTC

Ergebnisse

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13. Mai 2026, 22:15 UTC

Ergebnisse

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13. Mai 2026, 22:13 UTC

Ergebnisse

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13. Mai 2026, 22:12 UTC

Ergebnisse

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13. Mai 2026, 22:11 UTC

Ergebnisse

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13. Mai 2026, 22:11 UTC

Ergebnisse

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13. Mai 2026, 22:10 UTC

Ergebnisse

Xero Did Not Declare a Dividend>XRO.AU

13. Mai 2026, 22:10 UTC

Ergebnisse

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13. Mai 2026, 22:09 UTC

Ergebnisse

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13. Mai 2026, 22:00 UTC

Ergebnisse

Cisco to Shed Jobs for All-In AI Push -- Update

13. Mai 2026, 21:11 UTC

Ergebnisse

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Peer-Vergleich

Kursveränderung

Quidel Corp Prognose

Kursziel

By TipRanks

8.18% Vorteil

12-Monats-Prognose

Durchschnitt 12.03 USD  8.18%

Hoch 13 USD

Tief 11 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Quidel Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

6 ratings

1

Buy

4

Halten

1

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

Betriebsergebnis

$

Über Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat